ATE297902T1 - Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren - Google Patents

Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren

Info

Publication number
ATE297902T1
ATE297902T1 AT02251173T AT02251173T ATE297902T1 AT E297902 T1 ATE297902 T1 AT E297902T1 AT 02251173 T AT02251173 T AT 02251173T AT 02251173 T AT02251173 T AT 02251173T AT E297902 T1 ATE297902 T1 AT E297902T1
Authority
AT
Austria
Prior art keywords
reductase inhibitors
aldose reductase
pyridazinone derivatives
sulfonyl
sulfonyl pyridazinone
Prior art date
Application number
AT02251173T
Other languages
English (en)
Inventor
William Holt Martin
Banavara L Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE297902T1 publication Critical patent/ATE297902T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02251173T 2001-02-28 2002-02-20 Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren ATE297902T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27225401P 2001-02-28 2001-02-28

Publications (1)

Publication Number Publication Date
ATE297902T1 true ATE297902T1 (de) 2005-07-15

Family

ID=23039045

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02251173T ATE297902T1 (de) 2001-02-28 2002-02-20 Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren

Country Status (9)

Country Link
US (1) US6730674B2 (de)
EP (1) EP1236720B1 (de)
JP (1) JP2003128657A (de)
AT (1) ATE297902T1 (de)
BR (1) BR0200536A (de)
CA (1) CA2373395C (de)
DE (1) DE60204611T2 (de)
ES (1) ES2240657T3 (de)
MX (1) MXPA02002252A (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
AU2002236131B2 (en) * 2001-04-30 2005-04-14 Pfizer Products Inc. Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
KR20030061051A (ko) * 2002-01-07 2003-07-18 대한민국 (경상대학교 총장) 신규한 아렌(혹은 알케인)술폰일피리다진온 유도체, 이의제조방법 및 유기반응에서의 용도
DE602005025755D1 (de) * 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
JP5000649B2 (ja) * 2005-07-21 2012-08-15 エフ．ホフマン−ラ ロシュ アーゲー 甲状腺ホルモン受容体アゴニストとしてのピリダジノン誘導体
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
GB0907601D0 (en) * 2009-05-01 2009-06-10 Equateq Ltd Novel methods
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE574204A (fr) * 1958-12-24 1959-06-24 Henri Morren Dérives de sulfonyl-pyridazine
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
AU658887B2 (en) * 1991-03-28 1995-05-04 Pfizer Inc. Pyridazinone acetic acids as aldose reductase inhibitors
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU2002226634B2 (en) * 2001-03-30 2007-01-25 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia

Also Published As

Publication number Publication date
CA2373395A1 (en) 2002-08-28
US20030004139A1 (en) 2003-01-02
MXPA02002252A (es) 2002-09-30
EP1236720A1 (de) 2002-09-04
US6730674B2 (en) 2004-05-04
ES2240657T3 (es) 2005-10-16
DE60204611T2 (de) 2006-05-11
CA2373395C (en) 2006-01-10
JP2003128657A (ja) 2003-05-08
DE60204611D1 (de) 2005-07-21
EP1236720B1 (de) 2005-06-15
BR0200536A (pt) 2003-04-29

Similar Documents

Publication Publication Date Title
NL300927I1 (nl) tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
ATE396190T1 (de) Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase
ATE540928T1 (de) Isochinolinverbindungen und ihre medizinische verwendung
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
DK0931788T3 (da) Metalloproteasehæmmere
WO2004014913A3 (en) Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
NO20052927L (no) 2,4,6-trisubstituerte pyrimidiner av fosfotidylinositol (PI) 3-kinaseinhibitorer og deres anvendelse ved behandling av kreft
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
ATE283253T1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
WO2003082205A3 (en) Compounds and methods
DE60234164D1 (de) Neues a-liponsäurederivat und dessen verwendung
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
DK2000465T3 (da) Triazolonderivat
ATE297902T1 (de) Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
MXPA04006041A (es) Antivirales de piridoquinoxalina.
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
CA2452036A1 (en) 6-'2-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity
PL1637141T3 (pl) Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej
AU2003303098A1 (en) Process for the preparation of 2-aminomethylpyridine derivative
BR0002514A (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
HK1066214A1 (en) Process for the preparation of 4-(imidazol-1-yl) benzenesulfonamide derivatives
DK1499312T3 (da) Anvendelse af hydroxypyridonderivater til sårheling

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties